Federation des caisses Desjardins du Quebec’s Anika Therapeutics ANIK Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-16,908	Closed	-$495K	–	2113
2020 Q1	$495K	Buy	16,908 +11,760	+228%	+$476K	0.01%	645
2019 Q4	$267K	Buy	5,148 +2,325	+82%	+$135K	﹤0.01%	964
2019 Q3	$155K	Buy	+2,823	New	+$145K	﹤0.01%	1164
2017 Q2	–	Sell	-150	Closed	-$6.52K	–	2154
2017 Q1	$6.52K	Buy	+150	New	+$7.16K	﹤0.01%	1515

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's ANIK Position: Q2 2020 in Review

Federation des caisses Desjardins du Quebec sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 16,908 shares — an estimated $495K sold.

Federation des caisses Desjardins du Quebec first reported a position in ANIK in Q1 2017 and held it in 4 quarters. The position peaked at $495K in Q1 2020. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

Federation des caisses Desjardins du Quebec reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 16,908 Anika Therapeutics shares in Q2 2020, an estimated $495K.
Federation des caisses Desjardins du Quebec first reported a position in Anika Therapeutics in Q1 2017 and held it in 4 quarters.
Federation des caisses Desjardins du Quebec's Anika Therapeutics position peaked at $495K in Q1 2020.
158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2020, filed 30 Aug 2024.